SG11201400289SA - Glycosylated polypeptide and drug composition containing said polypeptide - Google Patents
Glycosylated polypeptide and drug composition containing said polypeptideInfo
- Publication number
- SG11201400289SA SG11201400289SA SG11201400289SA SG11201400289SA SG11201400289SA SG 11201400289S A SG11201400289S A SG 11201400289SA SG 11201400289S A SG11201400289S A SG 11201400289SA SG 11201400289S A SG11201400289S A SG 11201400289SA SG 11201400289S A SG11201400289S A SG 11201400289SA
- Authority
- SG
- Singapore
- Prior art keywords
- polypeptide
- composition containing
- drug composition
- glycosylated
- glycosylated polypeptide
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title 2
- 102000004196 processed proteins & peptides Human genes 0.000 title 2
- 108090000765 processed proteins & peptides Proteins 0.000 title 2
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
- C07K14/6555—Somatostatins at least 1 amino acid in D-form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011192202 | 2011-09-04 | ||
| PCT/JP2012/072380 WO2013032011A1 (ja) | 2011-09-04 | 2012-09-03 | 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201400289SA true SG11201400289SA (en) | 2014-05-29 |
Family
ID=47756483
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201400289SA SG11201400289SA (en) | 2011-09-04 | 2012-09-03 | Glycosylated polypeptide and drug composition containing said polypeptide |
| SG10201601324VA SG10201601324VA (en) | 2011-09-04 | 2012-09-03 | Glycosylated polypeptide and drug composition containing said polypeptide |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201601324VA SG10201601324VA (en) | 2011-09-04 | 2012-09-03 | Glycosylated polypeptide and drug composition containing said polypeptide |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9422357B2 (enExample) |
| EP (1) | EP2752424B1 (enExample) |
| JP (1) | JP6178238B2 (enExample) |
| KR (1) | KR102031998B1 (enExample) |
| CN (2) | CN103930441B (enExample) |
| AU (1) | AU2012302636B2 (enExample) |
| BR (1) | BR112014004784A2 (enExample) |
| CA (1) | CA2847334C (enExample) |
| DK (1) | DK2752424T3 (enExample) |
| IN (1) | IN2014CN02399A (enExample) |
| RU (1) | RU2624034C2 (enExample) |
| SG (2) | SG11201400289SA (enExample) |
| TW (1) | TWI662966B (enExample) |
| WO (1) | WO2013032011A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014004784A2 (pt) * | 2011-09-04 | 2017-03-21 | Glytech Inc | polipeptídeo glicosilado e composição de drogas contendo referido polipeptídeo |
| WO2013032012A1 (ja) | 2011-09-04 | 2013-03-07 | 株式会社糖鎖工学研究所 | 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物 |
| CN111855827B (zh) * | 2019-04-24 | 2022-09-16 | 岛津企业管理（中国）有限公司 | 多糖蛋白结合疫苗中多糖蛋白结合位点结合率的测定方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4000259A (en) * | 1975-06-16 | 1976-12-28 | American Home Products Corporation | Cyclic dodecapeptide analogs of somatostatin and intermediates |
| US4380953A (en) | 1978-09-11 | 1983-04-26 | Filper Corporation | Transfer mechanism in a peach pitter |
| US4310518A (en) | 1979-10-31 | 1982-01-12 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
| US4235886A (en) | 1979-10-31 | 1980-11-25 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
| US4280953A (en) * | 1979-11-08 | 1981-07-28 | The Salk Institute For Biological Studies | Glycosylated analogs of somatostatin |
| US4316891A (en) * | 1980-06-14 | 1982-02-23 | The Salk Institute For Biological Studies | Extended N-terminal somatostatin |
| LU85269A1 (fr) * | 1984-03-26 | 1985-10-14 | Techland S A | Composes nouveaux de somatostatine,procede pour leur synthese,preparation a usage veterinaire contenant lesdits composes et procede pour le traitement d'animaux |
| US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| HU206890B (en) | 1986-10-13 | 1993-01-28 | Sandoz Ag | Process for producing sugar-modified somatostatin peptide derivatives and pharmaceutical compositions containing them as active components |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| WO1997007205A1 (en) * | 1995-08-11 | 1997-02-27 | Novo Nordisk A/S | Method for preparing polypeptide variants |
| US5750499A (en) | 1995-10-18 | 1998-05-12 | The Salk Institute For Biological Studies | Receptor-selective somatostatin analogs |
| FI965181L (fi) * | 1996-12-20 | 1998-06-21 | Map Medical Technologies Oy | Polyalkoholi-peptidijohdannaiset |
| JP3385947B2 (ja) | 1998-01-05 | 2003-03-10 | 松下電器産業株式会社 | バルクフィーダ |
| AU5805500A (en) * | 1999-07-07 | 2001-01-30 | Maxygen Aps | A method for preparing modified polypeptides |
| US20030036181A1 (en) * | 2000-06-30 | 2003-02-20 | Okkels Jens Sigurd | Peptide extended glycosylated polypeptides |
| JP5398945B2 (ja) * | 2001-04-23 | 2014-01-29 | マリンクロッド エルエルシー | ＴｃおよびＲｅ標識放射活性グリコシル化オクトレオチド誘導体 |
| KR100775805B1 (ko) | 2001-06-19 | 2007-11-12 | 오츠카 가가쿠 가부시키가이샤 | 당쇄 아스파라긴 유도체의 제조 방법 |
| US7943763B2 (en) | 2002-07-05 | 2011-05-17 | Otsuka Chemical Holdings Co., Ltd. | Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides |
| CN100413889C (zh) * | 2002-12-24 | 2008-08-27 | 大塚化学株式会社 | 糖链天冬酰胺衍生物、糖链天冬酰胺和糖链以及它们的制造方法 |
| TWI330641B (en) | 2002-12-24 | 2010-09-21 | Yasuhiro Kajihara | Sugar chain asparagine derivatives |
| CA2511655C (en) | 2002-12-26 | 2009-07-07 | Otsuka Chemical Co., Ltd. | Three-branched sugar-chain asparagine derivatives, the sugar-chain asparagines, the sugar chains, and processes for producing these |
| WO2004070046A1 (ja) | 2003-02-04 | 2004-08-19 | Otsuka Chemical Co., Ltd. | 糖鎖アスパラギン誘導体の製造方法 |
| WO2004101619A1 (ja) * | 2003-05-15 | 2004-11-25 | Shionogi Co., Ltd. | 機能的糖ペプチドの合理的設計および合成 |
| KR100731875B1 (ko) | 2003-07-28 | 2007-06-25 | 오츠카 가가쿠 가부시키가이샤 | 아미노화 복합형 당사슬 유도체 및 그의 제조방법 |
| KR100604994B1 (ko) * | 2004-01-30 | 2006-07-26 | 한국생명공학연구원 | 알파1,6-만노실트랜스퍼라제를 코딩하는 한세눌라폴리모르파 기원의 신규 유전자 및 상기 유전자가 결손된한세눌라 폴리모르파 변이주를 이용한 재조합 당단백질생산 방법 |
| TWI342880B (en) | 2005-07-19 | 2011-06-01 | Otsuka Chemical Co Ltd | Method for producing sugar chain derivatives, and sugar chain derivatives |
| US20070025910A1 (en) * | 2005-07-29 | 2007-02-01 | Norenberg Jeffrey P | Anticancer therapy |
| EP1941902A1 (en) * | 2007-01-02 | 2008-07-09 | Novartis AG | Use of Somatostatin analogs in cluster headache |
| BRPI0813139A8 (pt) * | 2007-06-19 | 2019-01-29 | Glytech Inc | peptídeo glp-1 com adição de cadeia oligossacarídea |
| EP2288386A1 (en) | 2008-02-19 | 2011-03-02 | Asterion Limited | Modified linkers |
| BRPI0914889A2 (pt) * | 2008-06-17 | 2015-11-24 | Otsuka Chemical Co Ltd | peptídeo glp-1 adicionado de cadeia oligossacarídica |
| US20110118183A1 (en) * | 2008-06-27 | 2011-05-19 | Novo Nordisk Health Care Ag | N-glycosylated human growth hormone with prolonged circulatory half-life |
| WO2013032012A1 (ja) | 2011-09-04 | 2013-03-07 | 株式会社糖鎖工学研究所 | 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物 |
| BR112014004784A2 (pt) * | 2011-09-04 | 2017-03-21 | Glytech Inc | polipeptídeo glicosilado e composição de drogas contendo referido polipeptídeo |
-
2012
- 2012-09-03 BR BR112014004784A patent/BR112014004784A2/pt not_active IP Right Cessation
- 2012-09-03 CN CN201280053754.2A patent/CN103930441B/zh active Active
- 2012-09-03 CA CA2847334A patent/CA2847334C/en active Active
- 2012-09-03 SG SG11201400289SA patent/SG11201400289SA/en unknown
- 2012-09-03 IN IN2399CHN2014 patent/IN2014CN02399A/en unknown
- 2012-09-03 DK DK12828271T patent/DK2752424T3/da active
- 2012-09-03 JP JP2013531454A patent/JP6178238B2/ja active Active
- 2012-09-03 WO PCT/JP2012/072380 patent/WO2013032011A1/ja not_active Ceased
- 2012-09-03 EP EP12828271.2A patent/EP2752424B1/en active Active
- 2012-09-03 CN CN201710964257.2A patent/CN107522779B/zh active Active
- 2012-09-03 KR KR1020147008130A patent/KR102031998B1/ko active Active
- 2012-09-03 RU RU2014112046A patent/RU2624034C2/ru active
- 2012-09-03 SG SG10201601324VA patent/SG10201601324VA/en unknown
- 2012-09-03 US US14/342,359 patent/US9422357B2/en active Active
- 2012-09-03 AU AU2012302636A patent/AU2012302636B2/en active Active
- 2012-09-04 TW TW101132259A patent/TWI662966B/zh active
-
2016
- 2016-07-08 US US15/205,960 patent/US9937264B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9422357B2 (en) | 2016-08-23 |
| CN107522779B (zh) | 2021-10-26 |
| DK2752424T3 (da) | 2019-11-18 |
| RU2624034C2 (ru) | 2017-06-30 |
| WO2013032011A1 (ja) | 2013-03-07 |
| CN103930441B (zh) | 2017-11-17 |
| IN2014CN02399A (enExample) | 2015-06-19 |
| CN107522779A (zh) | 2017-12-29 |
| JPWO2013032011A1 (ja) | 2015-03-23 |
| TWI662966B (zh) | 2019-06-21 |
| CN103930441A (zh) | 2014-07-16 |
| JP6178238B2 (ja) | 2017-08-09 |
| EP2752424A1 (en) | 2014-07-09 |
| AU2012302636B2 (en) | 2016-09-15 |
| SG10201601324VA (en) | 2016-03-30 |
| TW201315478A (zh) | 2013-04-16 |
| EP2752424B1 (en) | 2019-09-11 |
| CA2847334C (en) | 2020-09-01 |
| KR102031998B1 (ko) | 2019-10-14 |
| EP2752424A4 (en) | 2015-04-22 |
| BR112014004784A2 (pt) | 2017-03-21 |
| US20170157260A1 (en) | 2017-06-08 |
| US20140336116A1 (en) | 2014-11-13 |
| KR20140059829A (ko) | 2014-05-16 |
| AU2012302636A1 (en) | 2014-03-20 |
| CA2847334A1 (en) | 2013-03-07 |
| RU2014112046A (ru) | 2015-11-27 |
| US9937264B2 (en) | 2018-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201601327RA (en) | Glycosylated polypeptide and drug composition containing said polypeptide | |
| IL262667B (en) | An isolated polynucleotide encoding a polypeptide and a pharmaceutical composition comprising the isolated polynucleotide | |
| ZA201305504B (en) | Compositions containing glycosylated antibodies and uses thereof | |
| AP3864A (en) | Pharmaceutical composition | |
| ZA201400762B (en) | Relaxin fusion polypeptides and uses thereof | |
| EP2718317A4 (en) | GLUCOSE-DEPENDENT INSULINOTROPE POLYPEPTIDE ANALOGUE, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | |
| IL228738B (en) | Antibody against cldn6, a pharmaceutical preparation including it and its use | |
| IL279676A (en) | Recombinant proteins and therapeutic uses | |
| GB201118232D0 (en) | Pharmaceutical composition | |
| PL2710039T3 (pl) | Kompozycje przeciwko CGRP i ich zastosowanie | |
| SG11201405578TA (en) | Pharmaceutical composition containing peptide | |
| ZA201302113B (en) | Caspofungin composition | |
| SG11201402139UA (en) | High mast2-affinity polypeptides and uses thereof | |
| ZA201207375B (en) | Stabilized pharmaceutical composition | |
| IL229956B (en) | Mphosphi peptides and vaccines including the same | |
| EP2727593A4 (en) | PHARMACEUTICAL COMPOSITION CONTAINING NICORANDIL | |
| PL2918267T3 (pl) | Kompozycja farmaceutyczna w postaci cząstek stałych | |
| ZA201400340B (en) | Pharmaceutical composition comprising ebastine and fluticasone | |
| SG10201601324VA (en) | Glycosylated polypeptide and drug composition containing said polypeptide | |
| IL221501A (en) | Medicinal product containing miramistine | |
| SG10201602076QA (en) | Glycosylated polypeptide and pharmaceutical composition containing same | |
| PL2709599T3 (pl) | Kompozycja farmaceutyczna zawierająca drotawerynę | |
| EP2711010A4 (en) | PHARMACEUTICAL COMPOSITION | |
| ZA201309537B (en) | Pharmaceutical composition comprising fexofedine | |
| GB201121236D0 (en) | Proteins and peptides |